title: A new anticancer agent (LY186641) interferes with creatinine assay.
abstract: The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.
authors.affiliation: Département de Biologie Clinique, Institut Gustave-Roussy, Villejuif,France.
authors.forename: M M
authors.initials: MM
authors.lastname: Bonnay
authors.forename: G
authors.initials: G
authors.lastname: Recondo
authors.forename: A J
authors.initials: AJ
authors.lastname: Gouyette
authors.forename: J P
authors.initials: JP
authors.lastname: Armand
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood*; D006801:Humans; D013453:Sulfonylurea Compounds / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; D003404:Creatinine; C058179:sulofenur